The Serum Institute of India has not yet received permission

The Serum Institute of India made it clear on Monday that the company has not yet received permission from the authorities to export its Covid-19 vaccine to other countries. The institute gave this information on Monday. Earlier on Sunday, the Indian government allowed the emergency use of two vaccines (covishield and covaxin) simultaneously.

Let us know that the ‘Covishield’ vaccine has been developed by Oxford and AstraZeneca, while it is being produced by the Indian company Serum Institute of India. At the same time, ‘Covaxin’ has been made by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR). Seven more vaccines of corona virus are also being made in India.

Simultaneously, the Institute of Serum reported that the cost of the Corona virus vaccine developed by AstraZeneca and the University of Oxford would cost the government $ 3-4 (Rs 219-292) per dose. SII, the world’s largest vaccine manufacturer, has a license to produce Covid-19 vaccine supplements and has already produced 50 million doses.

The Serum Institute of India has not yet received permission
The Serum Institute of India has not yet received permission

SII Chief Executive Officer (CEO) Adar Poonawala said that the company will start selling Kovishield in the first phase to the Government of India and GAVI (Global Alliances of Vaccine and Vaccination) countries. The vaccine will then be sold to the private market. Poonawala said that this vaccine would be given to India and GAVI countries on a priority basis.

He said that this vaccine will be made available to the private market only after meeting the needs of India and GAVI countries. Poonawala said that the vaccine will be given in the private market for $ 6-8. The government has indicated that it will need 300 million doses by July 2021. In the initial phase, this vaccine will be given to health workers and the elderly.